Fig. 2From: Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trialsMean percent change (± SD) from baseline in lumbar spine BMD in receiving risedronate. Patients were stratified into three cohorts by eGFR in baseline, and the mean percent change in lumbar spine BMD in each cohort was shown. *p < 0.001, significantly different from baselineBack to article page